Drug Profile
CIN 103
Alternative Names: CIN-103Latest Information Update: 11 Oct 2022
Price :
$50
*
At a glance
- Originator CinRx Pharma
- Class Irritable bowel syndrome therapies; Phenols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Irritable bowel syndrome
Most Recent Events
- 28 Dec 2023 Phase-II clinical trials in Irritable bowel syndrome in USA (PO) (NCT06153420) (CinRx Pharma website, October 2022)
- 03 Aug 2022 Cinphloro Pharma plans a phase II trial for Irritable bowel syndrome in 2022 (Cinphloro Pharma's pipeline, August 2022)
- 03 Aug 2022 Cinphloro Pharma completes a phase I trial in Irritable bowel syndrome (In volunteers) in USA (PO), before August 2022 (Cinphloro Pharma pipeline, August 2022)